<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="proliferate">
            <roleset id="proliferate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="thing becoming abundant&#x09;&#x09;&#x09;&#x09;// gene products //&#x0A;" />
                    <role n="1" descr="situation of becoming abundant&#x0A;" />
                    <role n="2" descr="location referring to organ, vitro&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>Adult naive T cells, which are at rest in normal conditions, are observed to proliferate strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Adult naive T cells, which are at rest in normal conditions, can proliferate strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Adult naive T cells, which are at rest in normal conditions, have proliferated when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Adult naive T cells, which are at rest in normal conditions, may proliferate strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Adult naive T cells, which are at rest in normal conditions, proliferated strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Cancer cells can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Cancer cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Cancer cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>HSC can continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>HSC is able to continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>HSC is observed to continue to proliferate strongly in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>HSC will continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>HSC will continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>HSC will continue to proliferate strongly in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Intrasplenically transplanted fetal liver cells, as our results have shown, have the ability to proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Intrasplenically transplanted fetal liver cells, as our results have shown, proliferated and differentiated into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Our observations illustrate that the human placenta can be endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Our observations illustrate that the human placenta is able to be endowed with the biochemical machinery to proliferate indefinitely throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Our observations illustrate that the human placenta is shown to be endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>The ability of EBD cells being observed to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>The ability of EBD cells that can proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>The ability of EBD cells that is able to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>The ability of EBD cells that is observed to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>The ability of EBD cells that may have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>The ability of EBD cells that may have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>The ability of EBD cells that will proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>The ability of EBD cells that will proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>These results show that intrasplenically transplanted fetal liver cells are able to proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>These results show that intrasplenically transplanted fetal liver cells are able to proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to significantly impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>Stat5ab-/-peripheral T cells regain the ability to proliferate upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Adult naive T cells can regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Adult naive T cells can regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Adult naive T cells have the probability of regaining the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Adult naive T cells have the probability of regaining the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Further, HSC are able to be proven to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Further, HSC could be observed to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Further, HSC have been found to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Further, HSC have been found to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Further, HSC have been proven to strongly proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>HIV-specific CD4+ T cells of viremic patients has the ability to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>HIV-specific CD4+ T cells of viremic patients is observed to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>HIV-specific CD4+ T cells of viremic patients is observed to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is able to be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is able to be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells will be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Our observations illustrate that endothelial cells can be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Our observations illustrate that endothelial cells has the ability to be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Our observations illustrate that endothelial cells has the ability to be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, could have proliferated strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, could have strongly proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, may proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will strongly proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has impaired their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has significantly impaired their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, significantly impaired their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impairs their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>endothelial cells have regained the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>endothelial cells have the probability of regaining the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>endothelial cells have the probability of regaining the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>endothelial cells will regain the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>endothelial cells, which are at rest in normal conditions, can strongly proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>endothelial cells, which are at rest in normal conditions, have the ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>endothelial cells, which are at rest in normal conditions, might have proliferated strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>endothelial cells, which are at rest in normal conditions, might have strongly proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>endothelial cells, which are at rest in normal conditions, proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>the androgen responsive prostate cancer cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>the androgen responsive prostate cancer cells are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>the androgen responsive prostate cancer cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>the human placenta are able to regain the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>the human placenta may have regained the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>the human placenta will regain the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>the human placenta, which are at rest in normal conditions, are observed to proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>the human placenta, which are at rest in normal conditions, could have proliferated strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>intrasplenically transplanted fetal liver cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>intrasplenically transplanted fetal liver cells has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
